EUVIMEDEUVIMED entdecken
Crossref

3079-LB: CMS-D008 Specifically Silences INHBE mRNA, Delivering Fat-Selective Weight Loss in Preclinical Study

JING JIA, JING SUN, YUTING WEI, JINYANG ZHANG, ZHIFENG ZHU, TAO ZHAO, QIONG XU, LIAN HE, DAZHOU YANG, RONG LU

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-3079-lb ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von JING JIA und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Even though current approved anti-obesity medications have been proven to be effective for the treatment of overweight and obesity, limitations such as muscle mass loss and poor tolerability have subsequently emerged, promoting the development of next-generation therapies. Human genetics provides strong evidence supporting INHBE as a compelling target for sustainable weight management. Inhibiting INHBE could represent a novel and promising approach for long-term weight maintenance with favorable metabolic profiles.

Methods

CMS-D008 is a novel siRNA drug targeting INHBE administered via subcutaneous injection. The pharmacological effects of CMS-D008 were evaluated in humanized INHBE DIO mice and obese cynomolgus macaque models. Body weight, body composition, INHBE mRNA levels, and the target protein Activin E were assessed over the course of the studies.

Results

In humanized INHBE DIO mouse models, weekly administration of CMS-D008 (1, 3, and 9 mpk) significantly reduced hepatic INHBE mRNA expression and serum Activin E protein levels, leading to marked decreases in body weight, total body fat, and regional fat mass while preserving lean mass. In obese cynomolgus macaque models, CMS-D008 (1.5, 4.5, 10 mpk) administered on Days 1 and 29 significantly lowered plasma Activin E expression and effectively suppressed weight gain induced by a sustained high-fat diet.

Conclusion

CMS-D008 effectively reduced INHBE mRNA expression and lowered its gene product Activin E protein levels in both humanized INHBE DIO mice and obese cynomolgus macaque models. This target engagement promoted healthy weight loss by reducing fat mass while retaining lean mass. Disclosure J. Jia: Employee; Ended; Shenzhen Kangzhe Biotechnology Co., Ltd. J. Sun: None. Y. Wei: None. J. Zhang: None. Z. Zhu: None. T. Zhao: None. Q. Xu: None. L. He: None. D. Yang: None. R. Lu: Employee; Current; Shenzhen Kangzhe Biotechnology Co., Ltd.

Zitieren

APA

JIA, J., SUN, J., WEI, Y., ZHANG, J., ZHU, Z., ZHAO, T., XU, Q., HE, L., YANG, D., & LU, R. (2026). 3079-LB: CMS-D008 Specifically Silences INHBE mRNA, Delivering Fat-Selective Weight Loss in Preclinical Study. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-3079-lb

Vancouver

JIA J, SUN J, WEI Y, ZHANG J, ZHU Z, ZHAO T, et al. 3079-LB: CMS-D008 Specifically Silences INHBE mRNA, Delivering Fat-Selective Weight Loss in Preclinical Study. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-3079-lb

BibTeX
@article{JIA2026,
  author = {JIA, JING and SUN, JING and WEI, YUTING and ZHANG, JINYANG and ZHU, ZHIFENG and ZHAO, TAO and XU, QIONG and HE, LIAN and YANG, DAZHOU and LU, RONG},
  title = {3079-LB: CMS-D008 Specifically Silences INHBE mRNA, Delivering Fat-Selective Weight Loss in Preclinical Study},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-3079-lb}
}
Kostenlos starten →